<SEC-DOCUMENT>0001178913-21-002041.txt : 20210609
<SEC-HEADER>0001178913-21-002041.hdr.sgml : 20210609
<ACCEPTANCE-DATETIME>20210609070148
ACCESSION NUMBER:		0001178913-21-002041
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210609
FILED AS OF DATE:		20210609
DATE AS OF CHANGE:		20210609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		211003958

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2126177.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES&#160;</font><font style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160;</font></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160;20549</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
      <div style="text-align: center; line-height: 1.25;">&#160;&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">of&#160;the Securities Exchange Act of 1934</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">For the month of June 2021<br>
        Commission File No.:001-35773</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">REDHILL BIOPHARMA LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">21 Ha'arba'a Street, Tel Aviv, 6473921, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.&#160;&#160;</div>
      <div style="text-align: center; text-indent: 14.2pt; line-height: 1.25;">Form 20-F &#9746; Form 40-F &#9744;</div>
      <div style="text-indent: 14.2pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____&#160;</div>
      <div style="text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Attached hereto and incorporated by reference herein is the following:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><a href="exhibit_1.htm">Exhibit 1<font style="font-family: Symbol, serif;">:</font>&#160;Registrant's press release entitled:
          &#8220;RedHill Biopharma to Present at the BIO Digital International Convention&#8221;</a></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Exhibit 99.1 (solely with respect to the first two paragraphs) to this Report on Form 6-K are hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the
        Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441),on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File
        No. 333-232776) on March 25, 2021 (File No. 333-254692) and on May 3, 2021 (File No. 333-255710), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on February 25, 2016 (Registration No. 333-209702), on
        July 23, 2018 (File No. 333-226278), on July 24, 2019 (File No. 333-232777) and on March 30, 2021 (File No. 333-254848).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.&#160;</div>
      <div style="text-align: justify; margin-left: 220.65pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z728e21bb1c2943388b683e987cb95eb0">

          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">REDHILL BIOPHARMA LTD.</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">(the "Registrant")</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 27%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25;">Date: June 9, 2021</div>
            </td>
            <td style="width: 3%; vertical-align: middle;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td style="width: 27%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">&#160;/s/ Dror Ben-Asher&#160;</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">Dror Ben-Asher&#160;</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">Chief Executive Officer</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">2<br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>EXHIBIT 1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 1</font></u><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><img width="150" height="89" src="image0.jpg"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="4" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z7294f5ba48b746a9a9646b9192085aaa">

            <tr>
              <td style="width: 100%; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="line-height: 1.25;">
                  <div style="text-align: center; line-height: 1.25;">Press Release</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><u>RedHill Biopharma to Present at the BIO Digital International Convention</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">TEL AVIV, Israel and RALEIGH, NC, June
          9, 2021 &#8211;</font>&#160;<u>RedHill Biopharma Ltd.</u> (Nasdaq: <u>RDHL</u>)
        (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill&#8217;s Chief Corporate &amp; Business Development Officer, will present a corporate overview at the BIO Digital International Convention,
        taking place June 14-18, 2021.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">The presentation will be available on the Company's website for 30 days from the start of the conference: <u>https://ir.redhillbio.com</u><u>.</u></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">About RedHill Biopharma</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">&#160;&#160;&#160;</font></div>
      <div style="text-align: justify; line-height: 1.25;">RedHill Biopharma Ltd. (Nasdaq: <u>RDHL</u>) is a
        specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, <font style="font-weight: bold;">Movantik</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>for opioid-induced constipation in adults<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>, <font style="font-weight: bold;">Talicia</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-weight: bold;">&#160;</font>for the treatment of <font style="font-style: italic;">Helicobacter pylori (H.
          pylori)</font> infection in adults<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup>, and <font style="font-weight: bold;">Aemcolo</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for the treatment of travelers&#8217; diarrhea in
        adults<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup>. RedHill&#8217;s key clinical late-stage development programs include: (i) <font style="font-weight: bold;">RHB-204</font>,<font style="font-weight: bold;">&#160;</font>with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) <font style="font-weight: bold;">opaganib (Yeliva</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-weight: bold;">, ABC294640)</font>, a first<font style="font-weight: bold;">-</font>in<font style="font-weight: bold;">-</font>class SK2 selective inhibitor targeting multiple indications with positive Phase 2
        COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) <font style="font-weight: bold;">RHB-107
          (upamostat)</font>, a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) <font style="font-weight: bold;">RHB-104</font>, with positive results from a first Phase 3 study for Crohn's disease; (v) <font style="font-weight: bold;">RHB-102</font>&#160;<font style="font-weight: bold;">(Bekinda</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-weight: bold;">)</font>,
        with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) <font style="font-weight: bold;">RHB</font>-<font style="font-weight: bold;">106</font>, an encapsulated bowel preparation. More information about the Company is available at <u>www.redhillbio.com</u> / <u>https://twitter.com/RedHillBio</u>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation
        Reform Act of 1995. Such statements may be preceded by the words &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;estimates,&#8221; &#8220;aims,&#8221; &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;potential&#8221; or similar words. Forward-looking statements
        are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&#8217;s control and cannot be predicted or quantified, and consequently, actual results may differ materially from
        those expressed or implied by such forward-looking statements. Such risks and uncertainties include risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company&#8217;s research, manufacturing, preclinical
        studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company&#8217;s ability to advance its
        therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company&#8217;s receipt of
        regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company&#8217;s therapeutic candidates
        and Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>; (v) the Company&#8217;s ability to successfully commercialize and promote Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and Aemcolo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>; (vi) the Company&#8217;s ability to establish and maintain corporate collaborations; (vii) the
        Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of
        the Company&#8217;s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company&#8217;s business model, strategic plans for its business and
        therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without
        infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company&#8217;s expenses, future revenues, capital
        requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company's Expanded Access Program; and (xiv) competition from other companies and technologies within the
        Company&#8217;s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including
        the Company's Annual Report on Form 20-F filed with the SEC on March 4, 2020. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written
        or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z67336822dc8d437e9c935ab4982966c3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25; font-weight: bold;">Company contact:</div>
              <div style="line-height: 1.25;">Adi Frish</div>
              <div style="line-height: 1.25;">Chief Corporate &amp; Business Development Officer</div>
              <div style="line-height: 1.25;">RedHill Biopharma</div>
              <div style="line-height: 1.25;">+972-54-6543-112</div>
              <div style="line-height: 1.25;"><u>adi@redhillbio.com</u></div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25; font-weight: bold;">Media contacts:</div>
              <div style="line-height: 1.25;"><font style="font-weight: bold;">U.S.:</font> Bryan Gibbs, Finn
                Partners</div>
              <div style="line-height: 1.25;">+1 212 529 2236</div>
              <div style="line-height: 1.25;"><u>bryan.gibbs@finnpartners.com</u></div>
              <div style="line-height: 1.25;"><font style="font-weight: bold;">UK:</font> Amber Fennell,
                Consilium</div>
              <div style="line-height: 1.25;">+44 (0) 7739 658 783</div>
              <div style="line-height: 1.25;"><u>fennell@consilium-comms.com</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <hr align="left" noshade="noshade" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Full prescribing information for Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (naloxegol) is available at: www.Movantik.com.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Full prescribing information for Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (omeprazole magnesium, amoxicillin and rifabutin) is available at:
        www.Talicia.com.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> Full prescribing information for Aemcolo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (rifamycin) is available at: www.Aemcolo.com.</div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2<br>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, 5@# 2(  A$! Q$!_\0
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M'RU8M!1115&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0":XCC7]U<(-TG^ZV3S]?SKN_"_Q"TGQ3?S65NDMO.HW1I/@&5>^,$\CT_\
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M?PKX:AFEA7^U+R,27$A'S*#R$'H!W]\^U=O7CW_#0.F_] *[_P"_R_X4?\-
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MX!YP6W8^E 'H=%%% !7)^%/^1F\8?]A&/_T1'765R?A3_D9O&'_81C_]$1T
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MZOI]SK=BG$6HV"!IMO82Q=2?]I<Y^M=I10!R7_"P])8;8K'6IIO^>*:9-O\
MU4#]:JS6FO>-B(-1M9-%\/DYDMV<?:KL?W6V\1H>XSD_C7;T4 ,AACMX(X88
MUCBC4(B*,!0.  /2N4N427XK6L<BAD;0IE96&009H\@UUU<G-_R5JS_[ DW_
M *.CH JQVNN^"F:'3;-]9\/Y)CMD<"YLQ_=3=Q(GH,Y'3M5D?$/25&V:QUJ"
M;_GC)IDV[]%(_6NMHH XJYO_ !#XM0V6EV-WH>FR<3ZA>*$G9>XBCZ@G^\V,
M>F:ZG2M+M-%TNWTZPB$5M;IL11_,^I)Y)]35RB@#FO%%A=7FK>&9;>!Y$MM2
M\V9E'W$\MQD^V2*Z6BB@ HHHH YKPA875C+XB-U \0N-9FGAW?QQE4 8>W!_
M*J6H:7K/A[7[K7- MUOK6^PU_II<(Q<#'FQ$\;L=0>N/R[*B@#DA\0M,C&+S
M3M;LY>\4VFRD_FH(/YU'+XLUG5AY'AOP[>;VX^V:I&;>"/\ VMI^=_H *[&B
M@#@M1\#72>$=32"?^T?$%Y)%<S7,V$\]XW5P@[*N%( Z#-='HFN76JR21W.A
M:CIK1H"6N@FQCZ*58Y_(5M44 <WX$L;K3?"%M:WD#PSK-<,4?J T\C#\P0?Q
MKI*** .;UNQNKCQCX6NX8'>"UDN3/(.B!H2JY^IXKI*** "N;\86-U?0Z*+6
M!Y3#J]M-)M_A16^9C["NDHH **** .;\?6-UJ7@?5+.R@>>XEC4)&G5OG4_T
MK8U73;;6=*NM-O$W6]S&8W ZX/<>XZU<HH XBRU;Q!X4A73];TN[U6TA&R#4
M]/3S'=!T\V/.X,!U(SFK1^(>D$;8;+6IY?\ GE'IDV[]5 _6NMHH X>X@\1^
M-1]FN;:30=!?_7*[@W=TO]WCB-3WY)_.EO+.\\,>+(M3TW1)KW2FTU+$PV17
MS("CDKA6(RI#8Z]J[>B@"M8737MC#<O:SVK2+DPS@!T]B 2,_C15FB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K%DT:9_&L&N"2/R(]/>T,?.XLTBMGTQA
M:VJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
